平均随访眼压、视野进展速率与现行目标眼压指南的关系
该研究纳入603只确诊青光眼患眼(非洲裔与青光眼评估研究),按基线视野MD分为三组,分析平均随访眼压与MD进展速率的关系。结果显示,在现行指南推荐的目标眼压范围内,各组中位MD斜率分别为-0.20、-0.19和-0.15 dB/y,组间无显著差异(p=0.63),提示遵循治疗指南有助于减缓各阶段青光眼的全局视野进展。
要点
- 稳定患眼平均随访眼压中位数:G1=15.0 mmHg、G2=13.2 mmHg、G3=11.9 mmHg(p<0.01)。
- 在指南目标眼压范围内,G1、G2、G3的中位MD斜率分别为-0.20、-0.19、-0.15 dB/y(p=0.63)。
- 遵循治疗指南有助于减缓不同疾病阶段的全局视野进展速率,种族组间无显著差异。
核心结论
- 在确诊青光眼样本中,遵循治疗指南有助于减缓不同疾病阶段的全局视野进展速率。
- 不同种族组间视野进展速率无显著差异。
研究设计与样本
- 研究纳入非洲裔与青光眼评估研究中603只确诊青光眼患眼的8598次24-2视野检查。
- 按基线视野MD将样本分为三组:G1(优于-5.0 dB)、G2(-5.0至-10 dB)、G3(差于-10 dB)。
- 分析现有目标眼压指南与各组MD进展速率的关系。
主要发现
- 稳定患眼平均随访眼压中位数及IQR:G1=15.0 mmHg(13.1至17.7)、G2=13.2 mmHg(11.6至14.3)、G3=11.9 mmHg(10.1至13.8),p<0.01。
- 在指南目标眼压范围内,中位MD斜率:G1<21 mmHg组为-0.20 dB/y(IQR:-0.43至-0.02),G2<18 mmHg组为-0.19 dB/y(IQR:-0.51至-0.01),G3<15 mmHg组为-0.15 dB/y(IQR:-0.47至0.05),p=0.63。
- 不同种族组间无显著差异。
关键数值与推荐
- 现行指南目标眼压上限:G1<21 mmHg、G2<18 mmHg、G3<15 mmHg。
临床怎么用
- 临床可参照现行指南设定的目标眼压上限管理不同阶段青光眼,以减缓全局视野进展。
- 需注意患眼间存在较大变异,应个体化评估与随访。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: To investigate if eyes presenting intraocular pressure (IOP) within the limits of current guideline-driven target IOP indeed experience slow rates of glaucomatous visual field (VF) progression. METHODS: A total of 8598 24-2 VF tests from 603 eyes from the African Descent and Glaucoma Evaluation Study with manifest glaucoma were included. The sample was split into three groups based on baseline VF mean deviation (MD): G1 (better than -5.0 dB), G2 (-5.0 to -10 dB) and G3 (worse than -10 dB). We investigated the relationship between existing target IOP guidelines and rates of MD progression in these groups. RESULTS: For stable eyes, the medians and IQR of the mean follow-up IOP were G1=15.0 mmHg (IQR: 13.1 to 17.7), G2=13.2 mmHg (IQR: 11.6 to 14.3) and G3=11.9 mmHg (IQR: 10.1 to 13.8) (p<0.01). When considering the mean follow-up IOP within the limits proposed by current guidelines, the median MD slopes were: -0.20 dB/y (IQR: -0.43 to -0.02) for G1<21 mmHg, -0.19 dB/y (IQR: -0.51 to -0.01) for G2<18 mmHg and -0.15 dB/y (IQR: -0.47 to 0.05) for G3<15 mmHg (p=0.63). There were no significant differences between racial groups. CONCLUSION: In a sample of patients with manifest glaucoma, despite substantial variability between eyes, adherence to treatment guidelines helped slow the rates of global VF progression at various stages of disease. TRIAL REGISTRATION NUMBER: clinicaltrials.gov Identifier: NCT00221923.
引用
- Melchior B, De Moraes CG, Paula JS, et al. Relationship between mean follow-up intraocular pressure, rates of visual field progression and current target intraocular pressure guidelines. Br J Ophthalmol. 2020. PMID: 33130556. doi:10.1136/bjophthalmol-2020-317406
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。